Drugmaker ships coronavirus vaccine for human testing

Drugmaker Moderna has shipped its first batch of a possible coronavirus vaccine for humans to government researchers for testing, just three months after the virus’s genome was sequenced.  

Shares of the biotech company soared early Tuesday, a day after the company said it sent vials to the National Institute of Allergy and Infectious Diseases for early-stage testing in the United States.

More than 80,000 people have been infected globally from the viral outbreak that began late last year in China.

A total of 35 cases have been reported in the United States and more than 2,600 people have died from the virus in mainland China, including one US citizen.

The vaccine is designed to target the spike protein on the surface of the virus that allows it to invade and infect human cells. 

Its development has moved very rapidly, but it could take 18 months or more for the shot to be ready, even it it proves safe for human use, experts have previously told DailyMail.com.   

Drugmaker Moderna has shipped its vaccine for coronavirus, which targets the spike on the outside of the coronavirus that lets it infect human cells (seen in the above image of the virus)

The drugmaker’s announcement comes as the Trump administration requests $2.5 billion to address the coronavirus outbreak in the US and abroad. 

Additional funding from Congress is intended to go to quarantine and containment efforts, as well as the development of vaccines and treatments for the virus. 

Moderna has been granted funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to expedite vaccine development. 

It has also partnered with the National Institutes of Health (NIH) and universities to use its cutting-edge vaccine development platform in the hopes of creating a preventive method for the disease as quickly as possible. 

Among the universities it’s worked with is the University of Texas, Austin, where researchers recently developed the first 3-D model of the virus’s spike protein. 

In order to map the protein, they had to recreate the virus component, and discovered that this had vaccine potential. 

The team there had been studying related viruses – those behind the 2003 SARS outbreak and the 2012 MERS outbreak – for years, and that gave them a leg up in researching the new virus. 

University of Texas has not confirmed that their vaccine candidate is the one shipped by Moderna, but Moderna described their vaccine as being based on the same structure the researchers there have been working on. 

Coronaviruses, as a family, are named by the resemblance of their shape to a corona, or crown (not to be confused, as many social media users have done, with the beer).  



Next Page